Armistice Capital’s BioLineRX BLRX Stock Holding History

Armistice Capital’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-69,926	Closed	-$2.59M	–	201
2022 Q3	$2.59M	Buy	+69,926	New	+$3.99M	0.04%	121

Other funds holding BLRX

ACM

Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

GWM

Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return

CCB

Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return

BAM

Belpointe Asset Management Reno, Nevada $3.06B AUM 23.82% 1-Year Est. Return

Armistice Capital's BLRX Position: Q4 2022 in Review

Armistice Capital sold out of BioLineRX (BLRX) in Q4 2022, closing a stake of 69,926 shares — an estimated $2.59M sold.

Armistice Capital first reported a position in BLRX in Q3 2022 and held it in 1 quarter. The position peaked at $2.59M in Q3 2022. 18 funds tracked by Wall St. Rank hold BLRX as of Q4 2022.

Armistice Capital reported no remaining BioLineRX position as of Q4 2022 after selling out during the quarter.
Armistice Capital sold 69,926 BioLineRX shares in Q4 2022, an estimated $2.59M.
Armistice Capital first reported a position in BioLineRX in Q3 2022 and held it in 1 quarter.
Armistice Capital's BioLineRX position peaked at $2.59M in Q3 2022.
18 funds tracked by Wall St. Rank held BioLineRX as of Q4 2022.

Based on Armistice Capital's 13F filing for Q4 2022, filed 14 Feb 2023.